Atrius Health Central OB/GYN CME Presents: OB/GYN Challenges and Controversies, 6/7/23
Claiming Credit for Session
Thank you for attending Atrius Health's OB/GYN meeting on June 7, 2023. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to take an evaluation to claim your credit on the following page.
Educational Needs Addressed
In this meeting, Atrius Health discussed the current challenges, guideline advancements and treatment in OB/GYN practice as identified by their internal specialists and CME planning committee. The latest practice data and findings were discussed with the goal of further improving internal practice and treatments.
Atrius Health OB/GYN Clinicians
At the completion of this activity, pharmacists will be able to:
- Describe the justification for withholding Rho(D) Immune Globulin in early pregnancy bleeding
- Diagnose and manage PCOS with all the evidence
- Perform appropriately and consistently to equivocal rubella and varicella serology and mixed and low colony count urine cultures in pregnancy
- Conduct personal practice in alignment with departmental and organizational goals
- Illustrate understanding of new steps in first trimester genetic testing
- Predict and comply with standards for maternity leave
- Describe and prescribe estrogen safely across the female lifespan
Faculty Presenters and Disclosures
Martha Richardson, MD
Obstetrics and Gynecology
Harvard Vanguard Medical Associates
The Copley Center
Drs. Finkelstein, Lombard, Mayhew, Plante, Stefansson, Vadnais, Weiss, and Mr. Fitzpatrick have no relevant financial relationships to disclose.
Dr. Horvath receives grant/research support from the Society of Family Planning Research Funding and is trainer for Organon.
Planning Committee and Disclosures
Kaila Anne Cutucchia, CNM; Caitlin Mayhew, CNM; Christopher Morrison, MD; Deborah Platek, MD; Martha Richardson, MD; and , of Atrius Health have no relevant financial relationships to disclose.
Meaghan Bride, NP is a consultant for Sebela Pharmaceuticals, is a speaker for Evofem Biosciences, and a trainer for Merck & Co., Inc. and Organon.
The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships with ineligible companies:
Michael Burk, BS – Operations Manager
Accreditor Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
The faculty members do not plan on discussing the unlabeled/investigational use of any commercial products.
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Atrius Health. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program includes 2.25 hours which meet the criteria of the Massachusetts Board of Registration in Medicine for risk management study.
Contact Hours: 3.25, of which 2 are eligible for pharmacology credit
Interprofessional Continuing Education Credit
This activity was planned by and for the healthcare team, and learners will receive 3.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
- 3.25 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.25 MA Risk Management
- 3.25 ANCC
- 2.00 ANCC Pharmacology
- 3.25 Participation